JP2008527017A - 神経ペプチド−2レセプター(y2r)アゴニスト活性を有するペプチド - Google Patents
神経ペプチド−2レセプター(y2r)アゴニスト活性を有するペプチド Download PDFInfo
- Publication number
- JP2008527017A JP2008527017A JP2007551586A JP2007551586A JP2008527017A JP 2008527017 A JP2008527017 A JP 2008527017A JP 2007551586 A JP2007551586 A JP 2007551586A JP 2007551586 A JP2007551586 A JP 2007551586A JP 2008527017 A JP2008527017 A JP 2008527017A
- Authority
- JP
- Japan
- Prior art keywords
- arg
- leu
- tyr
- neuropeptide
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000556 agonist Substances 0.000 title claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 title description 54
- 230000000694 effects Effects 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- 239000000018 receptor agonist Substances 0.000 claims abstract description 44
- 229940044601 receptor agonist Drugs 0.000 claims abstract description 44
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 208000008589 Obesity Diseases 0.000 claims abstract description 17
- 235000020824 obesity Nutrition 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 92
- 238000002360 preparation method Methods 0.000 claims description 78
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
- 229920001223 polyethylene glycol Chemical group 0.000 claims description 21
- 125000003827 glycol group Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- 229940076279 serotonin Drugs 0.000 claims description 10
- PHXRLXSFXHFCPA-UHFFFAOYSA-N 2-[4-(2-aminoethyl)piperazin-1-yl]acetic acid Chemical compound NCCN1CCN(CC(O)=O)CC1 PHXRLXSFXHFCPA-UHFFFAOYSA-N 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 108010064235 lysylglycine Proteins 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000006806 disease prevention Effects 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- XODBCXUINWJEKL-UHFFFAOYSA-N 3-dibenzofuran-4-ylpropanoic acid Chemical compound C12=CC=CC=C2OC2=C1C=CC=C2CCC(=O)O XODBCXUINWJEKL-UHFFFAOYSA-N 0.000 claims 3
- 238000009117 preventive therapy Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 abstract description 3
- 239000011347 resin Substances 0.000 description 118
- 229920005989 resin Polymers 0.000 description 118
- 239000000843 powder Substances 0.000 description 73
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 70
- 238000010532 solid phase synthesis reaction Methods 0.000 description 70
- 238000000746 purification Methods 0.000 description 68
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 66
- -1 NMelys Chemical compound 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 33
- 108010088847 Peptide YY Proteins 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 230000008878 coupling Effects 0.000 description 20
- 238000010168 coupling process Methods 0.000 description 20
- 238000005859 coupling reaction Methods 0.000 description 20
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 19
- 102100029909 Peptide YY Human genes 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 17
- 235000012631 food intake Nutrition 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 14
- 230000037406 food intake Effects 0.000 description 14
- 125000006239 protecting group Chemical group 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 9
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 description 9
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 8
- 101710151321 Melanostatin Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 description 8
- 102100028427 Pro-neuropeptide Y Human genes 0.000 description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 125000002015 acyclic group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000003295 arcuate nucleus Anatomy 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 3
- 229940097277 hygromycin b Drugs 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- SSJGXNSABQPEKM-SBUIBGKBSA-N pyy peptide Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 SSJGXNSABQPEKM-SBUIBGKBSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QTWZCODKTSUZJN-LJAQVGFWSA-N (2s)-5-[[amino-[(2,2,5,7,8-pentamethyl-3,4-dihydrochromen-6-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C(C(C)=C1C)=C(C)C2=C1OC(C)(C)CC2 QTWZCODKTSUZJN-LJAQVGFWSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- UPMGJEMWPQOACJ-UHFFFAOYSA-N 2-[4-[(2,4-dimethoxyphenyl)-(9h-fluoren-9-ylmethoxycarbonylamino)methyl]phenoxy]acetic acid Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(O)=O)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPMGJEMWPQOACJ-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical group OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000603245 Homo sapiens Neuropeptide Y receptor type 2 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102000029748 Neuropeptide Y2 receptor Human genes 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 108010089579 neuropeptide Y2 receptor Proteins 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 108010070727 peptide YY receptor Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- VCFCFPNRQDANPN-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCC)C(O)=O)C3=CC=CC=C3C2=C1 VCFCFPNRQDANPN-IBGZPJMESA-N 0.000 description 1
- URQNDMXCKJEUEW-DEOSSOPVSA-N (2s)-2-amino-6-[[(4-methylphenyl)-diphenylmethyl]amino]hexanoic acid Chemical compound C1=CC(C)=CC=C1C(NCCCC[C@H](N)C(O)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 URQNDMXCKJEUEW-DEOSSOPVSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- LUULAWGQWYTHTP-UHFFFAOYSA-N 1-methylpyrrolidin-2-one;piperidine Chemical compound C1CCNCC1.CN1CCCC1=O LUULAWGQWYTHTP-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OEBIVOHKFYSBPE-UHFFFAOYSA-N 4-Benzyloxybenzyl alcohol Chemical compound C1=CC(CO)=CC=C1OCC1=CC=CC=C1 OEBIVOHKFYSBPE-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 description 1
- 102000012301 Neuropeptide Y receptor Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004687 alkyl sulfinyl alkyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003151 isocoumarinyl group Chemical group C1(=O)OC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000001073 mediodorsal thalamic nucleus Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- MJAIRCQSHDYWQS-UHFFFAOYSA-N n-(9h-fluoren-9-ylmethoxy)formamide Chemical compound C1=CC=C2C(CONC=O)C3=CC=CC=C3C2=C1 MJAIRCQSHDYWQS-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 1
- 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000004590 pyridopyridyl group Chemical group N1=C(C=CC2=C1C=CC=N2)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000004963 sulfonylalkyl group Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【選択図】 なし
Description
(式中、Xは、N−ピペラジン−1−イル−4(3H)−キノゾリノン−3−酢酸(Pqa)、N−(5−O−カルボキシメチル)−セロトニン(Cms)、4−(2−アミノメチル)−6−ジベンゾフランプロパン酸、4−(1−ピペリジン−4−イル)−ブタン酸および4−(2−アミノエチル)−1−カルボキシメチルピペラジンから成る群より選ばれ、Yは、H、置換または非置換アルキル、置換または非置換低級アルキル、置換または非置換アリール、置換または非置換アルコキシまたはポリ(エチレン)グリコール部分であり、R1は、Ile、Ala、(D)Ile、N-メチルIle、Aib、1-1Aic、2-2Aic、AchまたはAcpであり、R2は、Lys、Ala、(D)Lys、NMelys、Nleまたは(Lys−Gly)であり、R3は、Arg、Ala、(D)Arg、N-メチルArg、Phe、3,4,5-トリフルオロPheまたは2,3,4,5,6-ペンタフルオロPheであり、R4は、His、Ala、(D)His、N-メチルHis、4-MeOApc、3-Palまたは4-Palであり、R5は、Tyr、Ala、(D)Tyr、N-メチルTyr、Trp、Tic、Bip、Dip、(1)Nal、(2)Nal、3,4,5-トリフルオロPheまたは2,3,4,5,6-ペンタフルオロPheであり、R6は、Leu、Ala、(D)LeuまたはN-メチルLeuであり、R7はAsn、Alaまたは(D)Asnであり、R8はLeu、Ala、(D)LeuまたはN-メチルLeuであり、R9はVal、Ala、(D)ValまたはN-メチルValであり、R10はThr、AlaまたはN-メチルThrであり、R11はArg、(D)ArgまたはN-メチルArgであり、R12はGlnまたはAlaであり、R13はArg、(D)ArgまたはN-メチルArgであり、およびR14は、Tyr、(D)TyrまたはN-メチルTyrである)の神経ペプチド−2レセプターアゴニスト、あるいはその薬学的に許容される塩が提供される。
(式中、Xは、N−ピペラジン−1−イル−4(3H)−キノゾリノン−3−酢酸(Pqa)、N−(5−O−カルボキシメチル)−セロトニン(Cms)、4−(2−アミノメチル)−6−ジベンゾフランプロパン酸、4−(1−ピペリジン−4−イル)−ブタン酸および4−(2−アミノエチル)−1−カルボキシメチルピペラジンから成る群より選ばれる部分であり、Yは、H、置換または非置換アルキル、置換または非置換低級アルキル、置換または非置換アリール、置換または非置換アルコキシまたはポリ(エチレン)グリコール部分であり、R1は、Ile、Ala、(D)Ile、N-メチルIle、Aib、1-1Aic、2-2Aic、AchまたはAcpであり、R2は、Lys、Ala、(D)Lys、NMelys、Nleまたは(Lys−Gly)である)の神経ペプチド−2 レセプターアゴニストあるいはその薬学的に許容される塩が提供される。
(式中、Xは、N−ピペラジン−1−イル−4(3H)−キノゾリノン−3−酢酸(Pqa)、N−(5−O−カルボキシメチル)−セロトニン(Cms)、4−(2−アミノメチル)−6−ジベンゾフランプロパン酸、4−(1−ピペリジン−4−イル)−ブタン酸および4−(2−アミノエチル)−1−カルボキシメチルピペラジンから成る群より選ばれ部分であり、Yは、H、置換または非置換アルキル、置換または非置換低級アルキル、置換または非置換アリール、置換または非置換アルコキシまたはポリ(エチレン)グリコール部分である)の神経ペプチド−2レセプターアゴニスト、あるいはその薬学的に許容される塩が提供される。
(式中、Xは、N−ピペラジン−1−イル−4(3H)−キノゾリノン−3−酢酸(Pqa)、N−(5−O−カルボキシメチル)−セロトニン(Cms)、4−(2−アミノメチル)−6−ジベンゾフランプロパン酸、4−(1−ピペリジン−4−イル)−ブタン酸および4−(2−アミノエチル)−1−カルボキシメチルピペラジンから成る群より選ばれ、Yは、H、置換または非置換アルキル、置換または非置換低級アルキル、置換または非置換アリール、置換または非置換アルコキシまたはポリ(エチレン)グリコール部分であり、R1は、Ile、Ala、(D)Ile、N-メチルIle、Aib、1-1Aic、2-2Aic、AchまたはAcpであり、R2は、Lys、Ala、(D)Lys、NMelys、Nleまたは(Lys−Gly)であり、R3は、Arg、Ala、(D)Arg、N-メチルArg、Phe、3,4,5-トリフルオロPhe、または2,3,4,5,6-ペンタフルオロPheであり、R4は、His、Ala、(D)His、N-メチルHis、4-MeOApc、3-Palまたは4-Palであり、R5は、Tyr、Ala、(D)Tyr、N-メチルTyr、Trp、Tic、Bip、Dip、(1)Nal、(2)Nal、3,4,5-トリフルオロPheまたは2,3,4,5,6-ペンタフルオロPheであり、R6は、Leu、Ala、(D)LeuまたはN-メチルLeuであり、R7はAsn、Alaまたは(D)Asnであり、R8はLeu、Ala、(D)LeuまたはN-メチルLeuであり、R9はVal、Ala、(D)ValまたはN-メチルValであり、R10はThr、AlaまたはN-メチルThrであり、R11はArg、(D)ArgまたはN-メチルArgであり、R12はGlnまたはAlaであり、R13はArg、(D)ArgまたはN-メチルArgであり、およびR14は、Tyr、(D)TyrまたはN-メチルTyrである)の神経ペプチド−2レセプターアゴニスト、あるいはその薬学的に許容される塩、を投与する工程を有する。
および式PYY3-4−Cms−PYY25-36:
の化合物を提供する。
、
の化合物を提供する。
Fmoc−Linker−BHA樹脂の調製
ベンズヒドリルアミンコポリスチレン−1%ジビニルベンゼン架橋樹脂(10.0g、9.3当量、100〜200ASTMメッシュ、Advanced ChemTech)をCH2Cl2100mL中で膨張させ、濾過し、CH2Cl2、6%DIPEA/CH2Cl2(2回)、CH2Cl2(2回)各100mLで連続して洗浄した。樹脂を25%DMF/CH2Cl2100mL中のp−((R,S)−α−(1−(9H−フルオレン−9−イル)−メトキシホルムアミド)−2,4−ジメトキシベンジル)−フェノキシ酢酸(Fmoc−Linker)(7.01g、13.0mmole)、N−ヒドロキシベンゾトリアゾール(2.16g、16.0mmole)及びジイソプロピル−カルボジイミド(2.04mL、13.0mmol)にて室温で24時間処理した。樹脂を濾過し、CH2Cl2(2回)、イソプロパノール(2回)、DMF、CH2Cl2(3回)各100mLで連続して洗浄した。Kaiserニンヒドリン分析は陰性であった。樹脂を減圧下で乾燥して、Fmoc−Linker−BHA樹脂16.12gを得た。この樹脂の一部分(3.5mg)をFmoc脱保護に付し、定量UV分析は、0.56mmol/gのローディングを示した。
フルオレニルメチルオキシカルボニル(Fmoc)化学を用いるApplied Biosystem社 433A合成器によるペプチド合成のプロトコール
Applied Biosystem社 433A合成器(カリフォルニア州、Foster City)による0.25mmolスケールのペプチド合成のため、FastMoc 0.25mmoleサイクルを、樹脂サンプリング又は非樹脂サンプリングのいずれか、41mL反応容器とともに使用した。Fmoc−アミノ酸樹脂をNMP2.1g、DMF中の0.45M HOBT/HBTU2g及び2M DIEAとともに溶解し、次に反応容器に移動した。
例:
H−Tyr−Pro−Ile−Lys−Pro−Glu−Ala−Pro−Gly−Glu−Asp−Ala−Ser−Pro−Glu−Glu−Leu−Asn−Arg−Tyr−Tyr−Ala−Ser−Leu−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(PYY1−36)(配列番号:3)の調製
上記ペプチドを、Fmoc化学を使用して、Applied Biosystem社 433A合成器上で合成した。合成器を、実施例2に記載のモジュールを使用して、ダブルカップリング用に調整した。合成を、実施例1のFmoc−Linker−BHA樹脂(450mg、0.25mmol)を使用して、0.25mmolスケールで実施した。開裂のため、合成の最後に、樹脂を振とう機上の反応容器に移動した。ペプチドを、97%TFA/3%H2O 13.5mL及びトリイソプロピルシラン1.5mLを使用して、室温で180分間、樹脂から開裂した。脱保護溶液を冷ET2O 100mLに加え、TFA 1mL及び冷ET2O 30mLで洗浄し、ペプチドを沈殿した。ペプチドを2×50mLポリプロピレン管で遠心分離した。個々の管内の沈殿物を単一の管に合わせ、冷ET2Oで3回洗浄し、実験室備付け配管につないだデシケーター内で乾燥した。
H−Ile−Lys−Pro−Glu−AIa−Pro−Gly−Glu−Asp−Ala−Ser−Pro−Glu−Glu−Leu−Asn−Arg−Tyr−Tyr−Ala−Ser−Leu−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(PYY3−36)(配列番号:4)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
Ac−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Ala−Arg−Tyr−NH2(配列番号:6)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Ala−Arg−Gln−Arg−Tyr−NH2(配列番号:7)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Ala−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:8)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Ala−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:9)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Ala−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:10)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Ala−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:11)の調製
H−Ile−Lys−Pqa−Arg−His−Ala−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:12)の調製
H−Ile−Lys−Pqa−Arg−Ala−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:13)の調製
H−Ile−Lys−Pqa−Ala−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:14)の調製
H−Ile−Ala−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
Ac−Ile−Ala−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
H−Ala−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−(D)Tyr−NH2の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−(D)Arg−Tyr−NH2の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−(D)Arg−Gln−Arg−Tyr−NH2の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−(D)Val−Thr−Arg−Gln−Arg−Tyr−NH2の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−(D)Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−(D)Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−(D)Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2の調製
H−Ile−Lys−Pqa−Arg−His−(D)Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2の調製
H−Ile−Lys−Pqa−Arg−(D)His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2の調製
H−Ile−Lys−Pqa−(D)Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2の調製
H−Ile−(D)Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
H−(D)Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−(NMe)Tyr−NH2(配列番号:15)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−(NMe)Arg−Tyr−NH2(配列番号:16)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−(NMe)Arg−Gln−Arg−Tyr−NH2(配列番号:17)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−(NMe)Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:18)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−(NMe)Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:19)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−Leu−Asn−(NMe)Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:20)の調製
H−Ile−Lys−Pqa−Arg−His−Tyr−(NMe)Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:21)の調製
H−Ile−Lys−Pqa−Arg−His−(NMe)Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:22)の調製
H−Ile−Lys−Pqa−Arg−(NMe)His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:23)の調製
H−Ile−Lys−Pqa−(NMe)Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:24)の調製
H−Ile−NMeLys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
H−NMeIle−Lys−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
H−Ile−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
Ac−Ile−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
Ac−Ile−Nle−Pqa−Phe−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:25)の調製
H−Ile−Lys−Pqa−Arg−His−Trp−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:26)の調製
H−Ile−Lys−Pqa−Ala−His−Trp−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:27)の調製
Ac−Ile−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−(D)Tyr−NH2の調製
Ac−Ile−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−N−メチルTyr−NH2(配列番号:15)の調製
シクロLys28−Asp32Ac−Ile−Nle−Pqa−Arg−His−Tyr−Lys−Asn−Leu−Val−Asp−Arg−Gln−Arg−Tyr−NH2(配列番号:28)の調製
H−Ile−Lys−Cms−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
H−Ile−Lys−Gly−Cms−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
シクロLys28−Aspu32Ac−Ile−Nle−Cms−Arg−His−Tyr−Lys−Asn−Leu−Val−Asp−Arg−Gln−Arg−Tyr−NH2(配列番号:28)の調製
Ac−Ile−Nle−Pqa−Arg−His−Tic−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:31)の調製
Ac−Ile−Nle−Pqa−Arg−His−Bip−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:32)の調製
Ac−Ile−Nle−Pqa−Arg−His−Dip−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:33)の調製
Ac−Ile−Nle−Pqa−Arg−His−(1)Nal−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:34)の調製
Ac−Ile−Nle−Pqa−Arg−His−(2)Nal−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:35)の調製
Ac−Ile−Nle−Pqa−Arg−His−(3,4,5トリフルオロPhe)−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:36)の調製
Ac−Ile−Nle−Pqa−Arg−His−(2,3,4,5,6ペンタフルオロPhe)−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:37)の調製
Ac−Ile−Nle−Pqa−Arg−(4−MeOApc)−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:38)の調製
Ac−Ile−Nle−Pqa−Arg−(3−Pal)−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:39)の調製
Ac−Ile−Nle−Pqa−Arg−(4−Pal)−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:40)の調製
Ac−Ile−Nle−Pqa−(3,4,5トリフルオロPhe)−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:41)の調製
Ac−Ile−Nle−Pqa−(2,3,4,5,6ペンタフルオロPhe)−HisTyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:42)の調製
Ac−Aib−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
Ac−1,1−Aic−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
Ac−1,1−Aic−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
Ac−2,2−Aic−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
Ac−Ach−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
Ac−Acp−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
H−Ile−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製
PEG(10,000)−Ile−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2(配列番号:5)の調製。
PEG (30,000)−Ile−Nle−Pqa−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2 (配列番号:5)の調製
実施例49の化合物の血漿安定性
実施例49のペプチドのヒト及びマウスの血漿安定性を測定した。この実施例において、実施例49のペプチド140μgを、37.5℃で0、40、90及び150分間、ヒト又はマウスのいずれかの血漿300μLでインキュベートした。POSRインキュベーション各サンプルを水中の0.1%酢酸中で50倍に希釈した。次に、希釈したサンプルをLC/UV/MSにより分析すると、安定していた。
実施例32の化合物の血漿安定性
実施例32のペプチドのヒト及びマウスの血漿安定性を測定した。この実施例において、実施例32のペプチド51μgを、37.5℃で0、40、90及び150分間、ヒト又はマウスのいずれかの血漿300μLでインキュベートした。POSRインキュベーション各サンプルを水中の0.1%酢酸中で50倍に希釈した。次に、希釈したサンプルをLC/UV/MSにより分析すると、安定していた。
cAMPアゴニストアッセイ
この実施例において、下記の物質を使用した:384−ウェルプレート;Tropix、cAMPスクリーンキット;cAMP ELISAシステム(Applied Biosystems社、,cat. #T1505;CS 20000);Forskolin(Calbiochem cat. # 344270);細胞:HEK293/hNPY2R;成長培地:ダルベッコー修飾イーグル培地((D-MEM、Gibco);10%ウシ胎仔血清(EBS、Gibco)、熱不活性化;1% ペニシリン/ストレプトマイシン(ペニシリン10000単位/ml:ストレプトマイシン10000mg/ml、Gibco);G418 500mg/ml(Geneticin、Gibco cat. # 11811-031);及びプレート培地:DMEM/F12 w/o フェノールレッド(Gibco); 10% FBS (Gibco, cat. # 10082-147)、熱不活性化; 1% ペニシリン/ストレプトマイシン(Gibco, cat. # 15140-122);G418 500 mg/ml(Geneticin, Gibco, cat. # 11811-031)。
食物摂取アッセイのインビボでの減少
この実施例においては、4回の実験で、実施例5,44,73及び74の化合物を4組のマウスに投与して、食物摂取の効果を計測した。8匹のマウスの実験グループとして、C57BL/6J雄マウス又はDIO(食餌誘発肥満)雄マウスを実験内で用いた。マウスは規則的な明サイクル(午前6時オン;午後6時オフ)で維持した。試験に先立ち、水を自由に与えてマウスを24時間絶食させた。試験の間、マウスはケージ毎に1匹で収容した。
CaFluxアッセイ
Hek−293細胞をGタンパク質キメラGaqi9で安定的にトランスフェクトし、ハイグロマイシン−B耐性遺伝子を、ヒトNPY2レセプター及びG418抗生物質選択で更にトランスフェクトした。両ハイグロマイシン−B及びG418の選択に従って、個々のクローンを、そのPYYに対する反応についてアッセイした。トランスフェクトした細胞を、10%胎仔血清、50μg/mLのハイグロマイシン−B、2mMのグルタミン、ペニシリン100U/mL、ストレプトマイシン100μg/mL及び250μg/mLのG418を補充したDMEM培地中で培養した。細胞をトリプシン−EDTAで回収し、ViaCount試薬を用いて計数した。細胞懸濁液の容積を完全成長培地で4.8×105細胞/mLに調整した。25μLのアリコートを384ウェルポリ−Dリシンでコートした黒色/透明なマイクロプレート(Falcon社)内に分与し、マイクロプレートを37℃ CO2インキュベータ内で一晩置いた。
下記の成分を含有するフィルムコーティング剤は常法により製造することができる:
成分 1錠当たり
核:
式(I)の化合物 10.0mg 200.0mg
微晶質セルロース 23.5mg 43.5mg
含水乳糖 60.0mg 70.0mg
ポビドンK30 12.5mg 15.0mg
グリコールデンプンナトリウム 12.5mg 17.0mg
ステアリン酸マグネシウム 1.5mg 4.5mg
(核重量) 120.0mg 350.0mg
フィルムコート:
ヒドロキシプロピルメチルセルロース 3.5mg 7.0mg
ポリエチレングリコール6000 0.8mg 1.6mg
タルク 1.3mg 2.6mg
酸化鉄(黄色) 0.8mg 1.6mg
二酸化チタン 0.8mg 1.6mg
下記の成分を含有するカプセル剤は、常法により製造することができる:
成分 1カプセル当たり
式(I)の化合物 25.0mg
乳糖 150.0mg
トウモロコシデンプン 20.0mg
タルク 5.0mg
成分を篩にかけ、混合し、サイズ2のカプセルに充填する。
注射剤は下記の組成を有することができる:
式(I)の化合物 3.0mg
ポリエチレングリコール400 150.0mg
酢酸 pH5.0にするのに十分な量
注射用水 全量を1.0mlにする量
活性成分を、ポリエチレングリコール400と注射用水(一部)の混合物に溶解する。酢酸によりpHを5.0に調整する。水の残量を加えて、容量を1.0mlに調整する。溶液を濾過し、適切な過剰量を使用してバイアルに充填し、滅菌する。
下記の成分を含有する軟ゼラチンカプセル剤は常法により製造できる:
カプセル剤内容
式(I)の化合物 5.0mg
黄ろう 8.0mg
硬化大豆油 8.0mg
部分的硬化植物油 34.0mg
大豆油 110.0mg
カプセル剤の重量 165.0mg
ゼラチンカプセル剤
ゼラチン 75.0mg
グリセロール85% 32.0mg
Karion 83 8.0mg(乾物)
二酸化チタン 0.4mg
酸化鉄黄 1.1mg
活性成分を、温かく溶融している他の成分に溶解し、混合物を適切な大きさの軟ゼラチンカプセルに充填する。充填された軟ゼラチンカプセル剤を、通常の手順に従って処理する。
下記の成分を含有するサッシェは常法により製造できる。
式(I)の化合物 50.0mg
乳糖、微細粉末 1015.0mg
微晶質セルロース(AVICEL PH 102) 1400.0mg
カルボキシメチルセルロースナトリウム 14.0mg
ポリビニルピロリドンK 30 10.0mg
ステアリン酸マグネシウム 10.0mg
風味添加剤 1.0mg
活性成分を、乳糖、微晶質セルロース及びカルボキシメチルセルロースナトリウムと混合し、水中のポリビニルピロリドンの混合物と共に造粒する。顆粒をステアリン酸マグネシウム及び風味添加剤と混合し、サッシェに充填する。
Claims (26)
- 式(I):
(式中:
Xは、N−ピペラジン−1−イル−4(3H)−キノゾリノン−3−酢酸(Pqa)、N−(5−O−カルボキシメチル)−セロトニン(Cms)、4−(2−アミノメチル)−6−ジベンゾフランプロパン酸、4−(1−ピペリジン−4−イル)−ブタン酸および4−(2−アミノエチル)−1−カルボキシメチルピペラジンから成る群より選ばれ、
Yは、H、置換または非置換アルキル、置換または非置換低級アルキル、置換または非置換アリール、置換または非置換アルコキシまたはポリ(エチレン)グリコール部分であり、
R1は、Ile、Ala、(D)Ile、N-メチルIle、Aib、1-1Aic、2-2Aic、AchまたはAcpであり、
R2は、Lys、Ala、(D)Lys、NMelys、Nleまたは(Lys−Gly)であり、
R3は、Arg、Ala、(D)Arg、N-メチルArg、Phe、3,4,5-トリフルオロPheまたは2,3,4,5,6-ペンタフルオロPheであり、
R4は、His、Ala、(D)His、N-メチルHis、4-MeOApc、3-Palまたは4-Palであり、
R5は、Tyr、Ala、(D)Tyr、N-メチルTyr、Trp、Tic、Bip、Dip、(1)Nal、(2)Nal、3,4,5-トリフルオロPheまたは2,3,4,5,6-ペンタフルオロPheであり、
R6は、Leu、Ala、(D)LeuまたはN-メチルLeuであり、
R7はAsn、Ala、または(D)Asnであり、
R8はLeu、Ala、(D)LeuまたはN-メチルLeuであり、
R9はVal、Ala、(D)ValまたはN-メチルValであり、
R10はThr、AlaまたはN-メチルThrであり、
R11はArg、(D)ArgまたはN-メチルArgであり、
R12はGlnまたはAlaであり、
R13はArg、(D)Arg、またはN-メチルArgであり、および
R14は、Tyr、(D)Tyr、またはN-メチルTyrである)
の、神経ペプチド−2レセプターアゴニスト、あるいは薬学的に許容されるそれらの塩。 - XがPqaである、請求項1記載の神経ペプチド−2レセプターアゴニスト。
- XがCmsである、請求項1記載の神経ペプチド−2レセプターアゴニスト。
- Yが(C1〜C6)のアルキル部分である、請求項1記載の神経ペプチド−2レセプターアゴニスト。
- 式(II):
(式中、
Xは、N−ピペラジン−1−イル−4(3H)−キノゾリノン−3−酢酸(Pqa)、N−(5−O−カルボキシメチル)−セロトニン(Cms)、4−(2−アミノメチル)−6−ジベンゾフランプロパン酸、4−(1−ピペリジン−4−イル)−ブタン酸および4−(2−アミノエチル)−1−カルボキシメチルピペラジンから成る群より選ばれる部分であり、
Yは、H、置換または非置換アルキル、置換または非置換低級アルキル、置換または非置換アリール、置換または非置換アルコキシまたはポリ(エチレン)グリコール部分であり、
R1は、Ile、Ala、(D)Ile、N-メチルIle、Aib、1-1Aic、2-2Aic、AchまたはAcpであり、および
R2は、Lys、Ala、(D)Lys、NMelys、Nleまたは(Lys−Gly)である)
の、神経ペプチド−2レセプターアゴニスト、あるいは薬学的に許容されるそれらの塩。 - XがPqaである、請求項5記載の神経ペプチド−2レセプターアゴニスト。
- XがCmsである、請求項5記載の神経ペプチド−2レセプターアゴニスト。
- 式(III):
Y−Ile−Lys−X−Arg−His−Tyr−Leu−Asn−Leu−Val−Thr−Arg−Gln−Arg−Tyr−NH2 (III)
(式中、
Xは、N−ピペラジン−1−イル−4(3H)−キノゾリノン−3−酢酸(Pqa)、N−(5−O−カルボキシメチル)−セロトニン(Cms)、4−(2−アミノメチル)−6−ジベンゾフランプロパン酸、4−(1−ピペリジン−4−イル)−ブタン酸および4−(2−アミノエチル)−1−カルボキシメチルピペラジンから成る群より選ばれ、
Yは、H、置換または非置換アルキル、置換または非置換低級アルキル、置換または非置換アリール、置換または非置換アルコキシまたはポリ(エチレン)グリコール部分である)
の、神経ペプチド−2レセプターアゴニスト、あるいは薬学的に許容されるそれらの塩。 - XがPqaである、請求項8記載の神経ペプチド−2レセプターアゴニスト。
- XがCmsである、請求項8記載の神経ペプチド−2レセプターアゴニスト。
-
から成る群より選ばれる、請求項1〜10のいずれか1項記載の、神経ペプチド−2レセプターアゴニスト。 -
から成る群より選ばれる、請求項1〜11のいずれか1項記載の、神経ペプチド−2レセプターアゴニスト。 - アミノ酸残基5〜24が長さ約8〜約11オングストロームの部分と置換された
PYY3-36誘導体を含む、神経ペプチド-2レセプターアゴニスト。 - 前記部分が長さ約9〜約11オングストロームである、請求項13記載の神経ペプチド−2レセプターアゴニスト。
- 前記部分が長さ約9〜約10オングストロームである、請求項14記載の神経ペプチド−2レセプターアゴニスト。
- 前記部分が長さ約8〜約10オングストロームである、請求項15記載の神経ペプチド−2レセプターアゴニスト。
- 前記部分が長さ約8〜約9オングストロームである、請求項16記載の神経ペプチド−2レセプターアゴニスト。
- 請求項1〜17のいずれか1項記載の化合物ならびに薬学的に許容される担体および/またはアジュバントを含む、医薬組成物。
- 治療用活性物質として使用するための、請求項1〜17のいずれか1項記載の化合物。
- 神経ペプチド−2レセプターアゴニストによってモジュレートされる疾病の治療および/または予防のための治療用活性物質として使用するための、請求項1〜17のいずれか1項記載の化合物。
- 神経ペプチド−2レセプターアゴニストによってモジュレートされる疾病の治療および/または予防療法のための、特に肥満の治療および/または予防療法のための方法であって、請求項1〜17のいずれか1項記載の化合物をヒトまたは動物に投与する工程を含む方法。
- 神経ペプチド−2レセプターアゴニストによってモジュレートされる疾病の治療および/または予防療法のための、請求項1〜17のいずれか1項記載の化合物の使用。
- 肥満の治療および/または予防療法のための、請求項1〜17のいずれか1項記載の化合物の使用。
- 神経ペプチド−2レセプターのアゴニストによってモジュレートされる疾病の治療および/または予防療法のための薬物の調製のための、請求項1〜17のいずれか1項記載の化合物の使用。
- 肥満の治療および/または予防療法のための薬物の調製のための、請求項1〜17のいずれか1項記載の化合物の使用。
- これより後に定義された発明。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64484005P | 2005-01-18 | 2005-01-18 | |
PCT/EP2006/000161 WO2006077035A1 (en) | 2005-01-18 | 2006-01-11 | Peptides with neuropeptide-2 receptor (y2r) agonist activity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008527017A true JP2008527017A (ja) | 2008-07-24 |
JP4633804B2 JP4633804B2 (ja) | 2011-02-16 |
Family
ID=36118121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007551586A Expired - Fee Related JP4633804B2 (ja) | 2005-01-18 | 2006-01-11 | 神経ペプチド−2レセプター(y2r)アゴニスト活性を有するペプチド |
Country Status (22)
Country | Link |
---|---|
US (1) | US7410949B2 (ja) |
EP (1) | EP1844070B1 (ja) |
JP (1) | JP4633804B2 (ja) |
KR (1) | KR100905380B1 (ja) |
CN (1) | CN101107266A (ja) |
AR (1) | AR051904A1 (ja) |
AT (1) | ATE500268T1 (ja) |
AU (1) | AU2006207659B2 (ja) |
BR (1) | BRPI0606675A2 (ja) |
CA (1) | CA2594423A1 (ja) |
DE (1) | DE602006020407D1 (ja) |
DK (1) | DK1844070T3 (ja) |
ES (1) | ES2359850T3 (ja) |
IL (1) | IL184428A0 (ja) |
MX (1) | MX2007008614A (ja) |
NO (1) | NO20073664L (ja) |
PL (1) | PL1844070T3 (ja) |
PT (1) | PT1844070E (ja) |
RU (1) | RU2383553C2 (ja) |
TW (1) | TWI309653B (ja) |
WO (1) | WO2006077035A1 (ja) |
ZA (1) | ZA200705674B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012502888A (ja) * | 2008-09-17 | 2012-02-02 | エフ.ホフマン−ラ ロシュ アーゲー | 神経ペプチド2受容体(y−2r)アゴニスト及びその使用 |
JP5767582B2 (ja) * | 2009-07-02 | 2015-08-19 | 武田薬品工業株式会社 | ペプチド及びその用途 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2430108C2 (ru) * | 2005-12-07 | 2011-09-27 | Ф.Хоффманн-Ля Рош Аг | Агонисты рецептора нейропептида-2 |
CN102202681A (zh) * | 2008-11-05 | 2011-09-28 | 霍夫曼-拉罗奇有限公司 | 神经肽-2受体(y-2r)激动剂及其用途 |
EP2477643A1 (en) * | 2009-09-18 | 2012-07-25 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
CN102596228A (zh) * | 2009-10-13 | 2012-07-18 | 霍夫曼-拉罗奇有限公司 | 神经肽-2受体(y-2r)激动剂 |
WO2012080471A1 (en) | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
SG11201407534PA (en) | 2012-06-13 | 2014-12-30 | Hoffmann La Roche | New diazaspirocycloalkane and azaspirocycloalkane |
AU2013322838B2 (en) | 2012-09-25 | 2018-02-01 | F. Hoffmann-La Roche Ag | New bicyclic derivatives |
AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
CN105764919B (zh) | 2013-11-15 | 2021-04-27 | 诺和诺德股份有限公司 | 在位置35具有β-高精氨酸置换的hPYY(1-36) |
US10246497B2 (en) | 2013-11-15 | 2019-04-02 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
RS56776B1 (sr) | 2013-11-26 | 2018-04-30 | Hoffmann La Roche | Derivati oktahidro-ciklobuta [1,2-c;3,4-c']dipirola kao inhibitori autotaksina |
CN110204550B (zh) | 2014-03-26 | 2022-05-17 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物 |
WO2015144609A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
JP6731958B2 (ja) | 2015-06-12 | 2020-07-29 | ノヴォ ノルディスク アー/エス | 選択的pyy化合物及びその使用 |
MX2020004504A (es) | 2015-09-04 | 2021-11-10 | Hoffmann La Roche | Derivados de fenoximetilo. |
KR20180054634A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물 |
RU2018112230A (ru) | 2015-09-24 | 2019-10-30 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов atx |
JP6845230B2 (ja) | 2015-09-24 | 2021-03-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | デュアルatx/ca阻害剤としての新規な二環式化合物 |
CA2983782A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
KR20190129924A (ko) | 2017-03-16 | 2019-11-20 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물 |
WO2019106193A1 (en) | 2017-12-01 | 2019-06-06 | University Of Copenhagen | Peptide hormone with one or more o-glycans |
EP3746111B1 (en) | 2018-02-02 | 2023-07-19 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
EP3800195A1 (en) * | 2019-10-03 | 2021-04-07 | Universitat de Barcelona | Peptide compounds for reducing side effects of cb1 receptor agonists |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002510704A (ja) * | 1998-04-03 | 2002-04-09 | ベー・エム・エル・アー・コルポーラティ・ベスローテン・フェンノートシャップ | テンプレートに結合したnpyy2−受容体アゴニスト |
WO2004066966A2 (en) * | 2003-01-17 | 2004-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Peptide yy analogs |
JP2007512365A (ja) * | 2003-11-25 | 2007-05-17 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 選択的神経ペプチドy2受容体作動薬 |
JP2007531711A (ja) * | 2004-02-11 | 2007-11-08 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
AU685803B2 (en) | 1993-03-29 | 1998-01-29 | University Of Cincinnati, The | Analogs of peptide YY and uses thereof |
-
2006
- 2006-01-10 US US11/328,743 patent/US7410949B2/en not_active Expired - Fee Related
- 2006-01-11 KR KR1020077018848A patent/KR100905380B1/ko not_active IP Right Cessation
- 2006-01-11 RU RU2007131504/04A patent/RU2383553C2/ru not_active IP Right Cessation
- 2006-01-11 BR BRPI0606675-5A patent/BRPI0606675A2/pt not_active Application Discontinuation
- 2006-01-11 PL PL06700451T patent/PL1844070T3/pl unknown
- 2006-01-11 CA CA002594423A patent/CA2594423A1/en not_active Abandoned
- 2006-01-11 PT PT06700451T patent/PT1844070E/pt unknown
- 2006-01-11 MX MX2007008614A patent/MX2007008614A/es active IP Right Grant
- 2006-01-11 EP EP06700451A patent/EP1844070B1/en not_active Not-in-force
- 2006-01-11 ES ES06700451T patent/ES2359850T3/es active Active
- 2006-01-11 JP JP2007551586A patent/JP4633804B2/ja not_active Expired - Fee Related
- 2006-01-11 DK DK06700451.5T patent/DK1844070T3/da active
- 2006-01-11 AT AT06700451T patent/ATE500268T1/de active
- 2006-01-11 DE DE602006020407T patent/DE602006020407D1/de active Active
- 2006-01-11 CN CNA2006800025981A patent/CN101107266A/zh active Pending
- 2006-01-11 AU AU2006207659A patent/AU2006207659B2/en not_active Ceased
- 2006-01-11 WO PCT/EP2006/000161 patent/WO2006077035A1/en active Application Filing
- 2006-01-16 AR ARP060100168A patent/AR051904A1/es active IP Right Grant
- 2006-01-16 TW TW095101606A patent/TWI309653B/zh not_active IP Right Cessation
-
2007
- 2007-07-05 IL IL184428A patent/IL184428A0/en unknown
- 2007-07-10 ZA ZA200705674A patent/ZA200705674B/xx unknown
- 2007-07-17 NO NO20073664A patent/NO20073664L/no not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002510704A (ja) * | 1998-04-03 | 2002-04-09 | ベー・エム・エル・アー・コルポーラティ・ベスローテン・フェンノートシャップ | テンプレートに結合したnpyy2−受容体アゴニスト |
WO2004066966A2 (en) * | 2003-01-17 | 2004-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Peptide yy analogs |
JP2007512365A (ja) * | 2003-11-25 | 2007-05-17 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 選択的神経ペプチドy2受容体作動薬 |
JP2007531711A (ja) * | 2004-02-11 | 2007-11-08 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012502888A (ja) * | 2008-09-17 | 2012-02-02 | エフ.ホフマン−ラ ロシュ アーゲー | 神経ペプチド2受容体(y−2r)アゴニスト及びその使用 |
JP5767582B2 (ja) * | 2009-07-02 | 2015-08-19 | 武田薬品工業株式会社 | ペプチド及びその用途 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0606675A2 (pt) | 2009-07-07 |
EP1844070B1 (en) | 2011-03-02 |
RU2007131504A (ru) | 2009-02-27 |
AU2006207659B2 (en) | 2009-10-29 |
WO2006077035A1 (en) | 2006-07-27 |
ATE500268T1 (de) | 2011-03-15 |
KR20070095422A (ko) | 2007-09-28 |
TWI309653B (en) | 2009-05-11 |
DE602006020407D1 (de) | 2011-04-14 |
KR100905380B1 (ko) | 2009-06-30 |
RU2383553C2 (ru) | 2010-03-10 |
DK1844070T3 (da) | 2011-06-14 |
PL1844070T3 (pl) | 2011-07-29 |
AU2006207659A1 (en) | 2006-07-27 |
US7410949B2 (en) | 2008-08-12 |
CA2594423A1 (en) | 2006-07-27 |
CN101107266A (zh) | 2008-01-16 |
JP4633804B2 (ja) | 2011-02-16 |
IL184428A0 (en) | 2007-10-31 |
US20060160742A1 (en) | 2006-07-20 |
EP1844070A1 (en) | 2007-10-17 |
PT1844070E (pt) | 2011-05-04 |
WO2006077035A9 (en) | 2006-10-26 |
ES2359850T3 (es) | 2011-05-27 |
ZA200705674B (en) | 2009-08-26 |
MX2007008614A (es) | 2007-09-11 |
NO20073664L (no) | 2007-09-28 |
AR051904A1 (es) | 2007-02-14 |
TW200637874A (en) | 2006-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4633804B2 (ja) | 神経ペプチド−2レセプター(y2r)アゴニスト活性を有するペプチド | |
JP5000663B2 (ja) | 神経ペプチド2受容体アゴニスト | |
US8299023B2 (en) | Neuropeptide-2 receptor (Y-2R) agonists | |
US20100179093A1 (en) | Neoropeptide-2-Receptor (Y-2R) Agonists | |
US20110172147A1 (en) | Neuropeptide-2 receptor (y-2r) agonists | |
MX2008007186A (en) | Neuropeptide-2 receptor-agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100525 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100727 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101022 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101116 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101117 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131126 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |